- $2.19m
- -$3.60m
- $0.82m
U.S. STOCKS ON THE MOVE-BlackRock, IPG Photonics, Estee Lauder
U.S. STOCKS ON THE MOVE-Amneal Pharma, 2seventy bio, Blue Water Biotech
Blue Water Biotech surges on purchase of six FDA-approved drugs
Brief: Blue Water Biotech Acquires Six FDA-Approved Drugs
Brief: Blue Water Biotech Reports Qtrly Net Loss Of $0.18 Per Share
Brief: Blue Water Vaccines Announces Corporate Name Change To Blue Water Biotech In Connection With Transition Into Commercial-Stage Biotechnology Company
Veru rises on sale of prostrate disorder drug business
Brief: Veru Sells Entadfi Business For $20 Million Plus Up To An Additional $80 Million From Sales Milestones
Brief: Blue Water Announces Acquisition Of Entadfi®, An FDA-Approved Benign Prostatic Hyperplasia Asset
Brief: Blue Water Vaccines Signs Research Agreement With University Of Texas Health Science Center
Brief: Blue Water Vaccines Says It Has Entered Into At Market Offering Agreement With H.C. Wainwright Relating To Sale Of Common Stock Offered By Prospectus Supplement
Brief: Blue Water Vaccines Reports Year 2022 Financial Results
Brief: Blue Water Vaccines Inc Files For Mixed Shelf Of Up To $100 Million – SEC Filing
Brief: Blue Water Vaccines Appoints Timothy Ramdeen To Its Board
U.S. STOCKS ON THE MOVE-Blue Water, Domino's Pizza, Tesla
Blue Water rises on vaccine development agreement
Brief: Blue Water Vaccines Announces Exclusive, Global License Agreement For Chlamydia Vaccine Candidate Development From The University Of Texas Health San Antonio
Blue Water Vaccines jumps on 5 mln share repurchase program
Brief: Blue Water Vaccines Reports Third Results